Joseph N. Samuel

Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class

Joseph N. Samuel, Christopher M. Booth, Elizabeth A. Eisenhauer et al. · JAMA Oncology · 2022 · 67 citations · Full text

Medicine, Oncology, Pharmacology +13

Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer

Konstantinos Gus Sidiropoulos, Nicole M. White, Anna Bui et al. · Oncoscience · 2014 · 33 citations · Full text

Medicine, Cancer Biology, Oncology +17

<scp>miRNAs</scp> dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways

Zsuzsanna Lichner, Qiang Ding, Sara Samaan et al. · The Journal of Pathology · 2015 · 32 citations

Medicine, Oncology, Urology +17

Kallikreins are involved in an miRNA network that contributes to prostate cancer progression

Sara Samaan, Zsuzsanna Lichner, Qiang Ding et al. · Biological Chemistry · 2014 · 16 citations

Medicine, Molecular Biology, Oncology +13

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Tian Qi Wang, Joseph N. Samuel, M. Catherine Brown et al. · Oncology and Therapy · 2018 · 13 citations · Full text

Pharmacy, Oncology, Toxicology +16